Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

The Clinical Utility of Optical Genome Mapping for the Assessment of Genomic Aberrations in Acute Lymphoblastic Leukemia

JL. Lühmann, M. Stelter, M. Wolter, J. Kater, J. Lentes, AK. Bergmann, M. Schieck, G. Göhring, A. Möricke, G. Cario, M. Žaliová, M. Schrappe, B. Schlegelberger, M. Stanulla, D. Steinemann

. 2021 ; 13 (17) : . [pub] 20210830

Language English Country Switzerland

Document type Journal Article

Acute lymphoblastic leukemia (ALL) is the most prevalent type of cancer occurring in children. ALL is characterized by structural and numeric genomic aberrations that strongly correlate with prognosis and clinical outcome. Usually, a combination of cyto- and molecular genetic methods (karyotyping, array-CGH, FISH, RT-PCR, RNA-Seq) is needed to identify all aberrations relevant for risk stratification. We investigated the feasibility of optical genome mapping (OGM), a DNA-based method, to detect these aberrations in an all-in-one approach. As proof of principle, twelve pediatric ALL samples were analyzed by OGM, and results were validated by comparing OGM data to results obtained from routine diagnostics. All genomic aberrations including translocations (e.g., dic(9;12)), aneuploidies (e.g., high hyperdiploidy) and copy number variations (e.g., IKZF1, PAX5) known from other techniques were also detected by OGM. Moreover, OGM was superior to well-established techniques for resolution of the more complex structure of a translocation t(12;21) and had a higher sensitivity for detection of copy number alterations. Importantly, a new and unknown gene fusion of JAK2 and NPAT due to a translocation t(9;11) was detected. We demonstrate the feasibility of OGM to detect well-established as well as new putative prognostic markers in an all-in-one approach in ALL. We hope that these limited results will be confirmed with testing of more samples in the future.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21024053
003      
CZ-PrNML
005      
20211013134053.0
007      
ta
008      
211006s2021 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/cancers13174388 $2 doi
035    __
$a (PubMed)34503197
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Lühmann, Jonathan Lukas $u Department of Human Genetics, Hannover Medical School, 30625 Hannover, Germany
245    14
$a The Clinical Utility of Optical Genome Mapping for the Assessment of Genomic Aberrations in Acute Lymphoblastic Leukemia / $c JL. Lühmann, M. Stelter, M. Wolter, J. Kater, J. Lentes, AK. Bergmann, M. Schieck, G. Göhring, A. Möricke, G. Cario, M. Žaliová, M. Schrappe, B. Schlegelberger, M. Stanulla, D. Steinemann
520    9_
$a Acute lymphoblastic leukemia (ALL) is the most prevalent type of cancer occurring in children. ALL is characterized by structural and numeric genomic aberrations that strongly correlate with prognosis and clinical outcome. Usually, a combination of cyto- and molecular genetic methods (karyotyping, array-CGH, FISH, RT-PCR, RNA-Seq) is needed to identify all aberrations relevant for risk stratification. We investigated the feasibility of optical genome mapping (OGM), a DNA-based method, to detect these aberrations in an all-in-one approach. As proof of principle, twelve pediatric ALL samples were analyzed by OGM, and results were validated by comparing OGM data to results obtained from routine diagnostics. All genomic aberrations including translocations (e.g., dic(9;12)), aneuploidies (e.g., high hyperdiploidy) and copy number variations (e.g., IKZF1, PAX5) known from other techniques were also detected by OGM. Moreover, OGM was superior to well-established techniques for resolution of the more complex structure of a translocation t(12;21) and had a higher sensitivity for detection of copy number alterations. Importantly, a new and unknown gene fusion of JAK2 and NPAT due to a translocation t(9;11) was detected. We demonstrate the feasibility of OGM to detect well-established as well as new putative prognostic markers in an all-in-one approach in ALL. We hope that these limited results will be confirmed with testing of more samples in the future.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Stelter, Marie $u Department of Human Genetics, Hannover Medical School, 30625 Hannover, Germany
700    1_
$a Wolter, Marie $u Department of Human Genetics, Hannover Medical School, 30625 Hannover, Germany
700    1_
$a Kater, Josephine $u Department of Human Genetics, Hannover Medical School, 30625 Hannover, Germany
700    1_
$a Lentes, Jana $u Department of Human Genetics, Hannover Medical School, 30625 Hannover, Germany
700    1_
$a Bergmann, Anke Katharina $u Department of Human Genetics, Hannover Medical School, 30625 Hannover, Germany
700    1_
$a Schieck, Maximilian $u Department of Human Genetics, Hannover Medical School, 30625 Hannover, Germany
700    1_
$a Göhring, Gudrun $u Department of Human Genetics, Hannover Medical School, 30625 Hannover, Germany
700    1_
$a Möricke, Anja $u Department of Pediatrics I, ALL-BFM Study Group, Christian-Albrechts University Kiel and University Medical Center Schleswig-Holstein, 24105 Kiel, Germany
700    1_
$a Cario, Gunnar $u Department of Pediatrics I, ALL-BFM Study Group, Christian-Albrechts University Kiel and University Medical Center Schleswig-Holstein, 24105 Kiel, Germany
700    1_
$a Žaliová, Markéta $u Department of Paediatric Haematology and Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, CZ-15006 Prague, Czech Republic
700    1_
$a Schrappe, Martin $u Department of Pediatrics I, ALL-BFM Study Group, Christian-Albrechts University Kiel and University Medical Center Schleswig-Holstein, 24105 Kiel, Germany
700    1_
$a Schlegelberger, Brigitte $u Department of Human Genetics, Hannover Medical School, 30625 Hannover, Germany
700    1_
$a Stanulla, Martin $u Pediatric Hematology and Oncology, Hannover Medical School, 30625 Hannover, Germany
700    1_
$a Steinemann, Doris $u Department of Human Genetics, Hannover Medical School, 30625 Hannover, Germany
773    0_
$w MED00173178 $t Cancers $x 2072-6694 $g Roč. 13, č. 17 (2021)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34503197 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20211006 $b ABA008
991    __
$a 20211013134050 $b ABA008
999    __
$a ind $b bmc $g 1708175 $s 1144550
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 13 $c 17 $e 20210830 $i 2072-6694 $m Cancers $n Cancers $x MED00173178
LZP    __
$a Pubmed-20211006

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...